Cytokine Signalling Forum

Publications





July 15

Long-term Safety of Tocilizumab: Results from 3 Years of Followup Postmarketing Surveillance of 5573 Patients with Rheumatoid Arthritis in Japan

Kazuhiko Yamamoto, Hajime Goto, Kenzo Hirao, Atsuo Nakajima, Hideki Origasa, Kunihiko Tanaka, Minako Tomobe and Kyoichi Totsuka.
The Journal of Rheumatology. 1 June 2015 DOI: 10.3899/jrheum.141210 [Epub ahead of print]

The humanised anti-interleukin 6 receptor monoclonal antibody tocilizumab (TCZ) has been available in clinical practice for several years. The purpose of this study was to evaluate the long-term safety of for the treatment of RA in a real-world clinical setting as a long-term extension of a single-arm, observational post marketing surveillance study. Data on selected adverse events (AEs) - fatal events, serious infection, malignancy, GI perforation, and serious cardiac dysfunction - were collect...

Keywords: IL-6, Tocilizumab, Clinical, Safety